Market Overview:
The global genomic biomarker market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing demand for personalized medicine, rising prevalence of cancer and other diseases, and technological advancements in genomic biomarkers. The protein marker segment is expected to dominate the global genomic biomarker market in terms of revenue by 2030. This can be attributed to the increasing demand for protein-based diagnostics and growing applications of protein markers in various industries such as hospitals, research laboratories, and pharmaceuticals companies. The nucleic acid marker segment is projected to grow at a higher CAGR during the forecast period owing to its growing use in molecular diagnostics and precision medicine. In terms of application, hospitals are expected to hold the largest share of the global genomic biomarker market by 2030 owingtothe increasing demand for early diagnosisand treatmentof various diseases such as cancerous tumors and heart disorders.
Product Definition:
Genomic biomarkers are DNA sequences that can be used to identify and track the progress of diseases, or the effects of treatments. Genomic biomarkers can be used to diagnose diseases, monitor patient progress, and select therapies.
Protein Marker:
Protein marker is a substance that is added to a particular protein for the purpose of studying, detecting or mapping its function in living organisms. Protein markers are used as genetic biomarkers for disease diagnosis and prognosis purposes. They are also being studied as potential drug targets and new therapeutic agents.
Nucleic Acid Marker:
Nucleic acid marker is a substance that is used for the detection of genetic material such as DNA or RNA in biological fluids. It can be either naturally occurring (such as blood, urine, and saliva) or synthetic (polymerase chain reaction-based). Nucleic acid markers are increasingly being employed in clinical diagnostics due to their ability to provide rapid results with high sensitivity and specificity.
Application Insights:
The hospitals segment dominated the global genomic biomarker market in 2017 and is expected to continue its dominance over the forecast period. This can be attributed to factors such as increasing prevalence of chronic diseases, growing geriatric population, and rising number of hospital-acquired infections. Moreover, a rise in demand for point-of-care diagnostic tests has also fueled growth.
Genomic biomarkers are increasingly being used in research settings as well as clinical trials owing to their ability to identify genetic abnormalities that may lead to various diseases with greater sensitivity than conventional methods. Increasing R&D activities pertainingto gene mapping and identification by companies & institutions for drug discovery & developmentis further anticipated to fuel growth during the forecast period. Increasing government fundingfor translational biomedical research along with favorable reimbursement policiesis projectedto drive demand from diagnostic laboratories over the next eight years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased government funding for genomic research, and rising prevalence of chronic diseases in this region. For instance, as per a recent study published by National Institutes of Health (NIH), from 2010 to 2015, there was an increase of 43% in funding for genomics at NIH. Furthermore high-throughput technologies are widely used across various fields such as agriculture & food science; drug discovery and development; forensics; environmental sciences; human health & disease management etc., which is also contributing towards regional growth.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing R&D investments by companies and academic institutes coupled with growing healthcare infrastructure facilities mainly due to population expansion over here.
Growth Factors:
- Increasing demand for personalized medicines
- Rising prevalence of cancer and other diseases
- Advances in genomic sequencing technology
- Growing investment in life sciences research
- Proliferation of genomics-based diagnostics
Scope Of The Report
Report Attributes
Report Details
Report Title
Genomic Biomarker Market Research Report
By Type
Protein Marker, Nucleic Acid Marker, Other
By Application
Hospitals, Diagnostic and research laboratories
By Companies
Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Genomic Biomarker Market Report Segments:
The global Genomic Biomarker market is segmented on the basis of:
Types
Protein Marker, Nucleic Acid Marker, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic and research laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bio-Rad
- Beckman Coulter
- Myriad Genetics
- Thermo Fisher Scientific
- Roche
- QIAGEN
- Epigenomics
- Almac
- Pfizer
- Human Longevity
- ValiRx
- Personalis
- Eagle Genomics
- Empire Genomics
- Agilent
- Illumina
Highlights of The Genomic Biomarker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protein Marker
- Nucleic Acid Marker
- Other
- By Application:
- Hospitals
- Diagnostic and research laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genomic Biomarker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A genomic biomarker is a genetic marker that can be used to identify a specific individual or group of individuals. Genomic biomarkers are often found in cancerous tissues, and can help doctors determine the stage of the cancer, as well as which treatments may be most effective.
Some of the major players in the genomic biomarker market are Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina.
The genomic biomarker market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genomic Biomarker Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genomic Biomarker Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genomic Biomarker Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genomic Biomarker Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genomic Biomarker Market Size & Forecast, 2020-2028
4.5.1 Genomic Biomarker Market Size and Y-o-Y Growth
4.5.2 Genomic Biomarker Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Protein Marker
5.2.2 Nucleic Acid Marker
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic and research laboratories
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genomic Biomarker Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genomic Biomarker Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Protein Marker
9.6.2 Nucleic Acid Marker
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic and research laboratories
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Protein Marker
10.6.2 Nucleic Acid Marker
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic and research laboratories
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Protein Marker
11.6.2 Nucleic Acid Marker
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic and research laboratories
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Protein Marker
12.6.2 Nucleic Acid Marker
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic and research laboratories
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Protein Marker
13.6.2 Nucleic Acid Marker
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic and research laboratories
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genomic Biomarker Market: Competitive Dashboard
14.2 Global Genomic Biomarker Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bio-Rad
14.3.2 Beckman Coulter
14.3.3 Myriad Genetics
14.3.4 Thermo Fisher Scientific
14.3.5 Roche
14.3.6 QIAGEN
14.3.7 Epigenomics
14.3.8 Almac
14.3.9 Pfizer
14.3.10 Human Longevity
14.3.11 ValiRx
14.3.12 Personalis
14.3.13 Eagle Genomics
14.3.14 Empire Genomics
14.3.15 Agilent
14.3.16 Illumina
